Foralumab Clinical Trials (2026): 10 Studies for Non-Active Secondary Progressive Multiple Sclerosis & Secondary Progressive Multiple Sclerosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Foralumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Non-Active Secondary Progressive Multiple Sclerosis & Secondary Progressive Multiple Sclerosis) and 157 total planned enrollment. 3 Foralumab clinical trials are actively recruiting at 3 U.S. sites across 1 state. Most recent activity: NCT06868628 (Apr 2027).
Where to Participate: All Foralumab Trial Sites in the U.S. (3 sites across 1 state)
Every actively recruiting Foralumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MA | Brigham and Women's Hospital | Boston02115 | NCT06868628 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT06890923 | Map |
| MA | Center for Alzheimer Research and Treatment, Brigham and Women's Hospital | Boston02115 | NCT06489548 | Map |
Foralumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | available | Total |
|---|---|---|---|---|---|---|
| P1 | 1 | 2 | 3 | |||
| P2 | 3 | 1 | 2 | 6 | ||
| N/A | 1 | 1 |
Recruiting Foralumab clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06868628 | MSAA Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | P2 | Multiple System Atrophy | 5 | May 2025 |
| NCT06489548 | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease | P2 | Dementia | 16 | Sep 2025 |
| NCT06890923 | TILS-022Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | P2 | Non-Active Secondary Progressive Multiple Sclerosis | 55 | Mar 2025 |
Foralumab clinical trials by indication
Non-Active Secondary Progressive Multiple Sclerosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06890923 | TILS-022 | P2 | recruiting | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis |
| NCT06802328 | — | N/A | available | Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients |
Dementia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06489548 | — | P2 | recruiting | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease |
Multiple System Atrophy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06868628 | MSA | P2 | recruiting | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) |
Secondary Progressive Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06292923 | — | P2 | active not recruiting | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients |
Crohn's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05028946 | — | P1 | withdrawn | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease |
Covid19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04983446 | — | P2 | withdrawn | In-patient COVID-19 Study of Intranasal Foralumab |
Primary Progressive Multiple Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05029609 | — | P1 | withdrawn | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS |
Safety (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06879067 | — | P1 | completed | Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers |
NASH - Nonalcoholic Steatohepatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03291249 | — | P2 | withdrawn | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM |
Foralumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MSA | NCT06868628 | P2 | recruiting | Multiple System Atrophy | 5 | PMID 35445419 |
| TILS-022 | NCT06890923 | P2 | recruiting | Non-Active Secondary Progressive Multiple Sclerosis | 55 | — |
Terminated and withdrawn Foralumab trials (4)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05028946withdrawnA Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
- NCT05029609withdrawnPhase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
- NCT04983446withdrawnIn-patient COVID-19 Study of Intranasal Foralumab
- NCT03291249withdrawnAssessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
All Foralumab trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06868628 | MSA | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | P2 | recruiting | 5 | Tiziana Life Sciences LTD | May 2025 |
| NCT06489548 | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease | P2 | recruiting | 16 | Brigham and Women's Hospital | Sep 2025 | |
| NCT06292923 | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | P2 | active not recruiting | 54 | Tiziana Life Sciences LTD | Nov 2023 | |
| NCT06890923 | TILS-022 | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | P2 | recruiting | 55 | Tiziana Life Sciences LTD | Mar 2025 |
| NCT06802328 | Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients | — | available | 0 | Tiziana Life Sciences LTD | — | |
| NCT05028946 | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease | P1 | withdrawn | 0 | Tiziana Life Sciences LTD | May 2022 | |
| NCT05029609 | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS | P1 | withdrawn | 0 | Tiziana Life Sciences LTD | Oct 2021 | |
| NCT04983446 | In-patient COVID-19 Study of Intranasal Foralumab | P2 | withdrawn | 0 | Tiziana Life Sciences LTD | Apr 2022 | |
| NCT06879067 | Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers | P1 | completed | 27 | Tiziana Life Sciences LTD | Nov 2018 | |
| NCT03291249 | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM | P2 | withdrawn | 0 | Tiziana Life Sciences LTD | Dec 2017 |
Foralumab clinical trials: frequently asked questions
- How many Foralumab clinical trials are there?
- 10 Foralumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 1 is marked completed.
- Are Foralumab clinical trials recruiting in 2026?
- Yes — 3 Foralumab trials are actively recruiting in 2026, with 3 U.S. sites across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is Foralumab being studied for?
- Foralumab is being studied for Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, COVID-19 Respiratory Infection, Covid19, Crohn's Disease and 12 more. The trials are grouped by indication on this page.
- What phase is Foralumab in?
- Foralumab clinical trials span 6 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Foralumab clinical trials?
- The lead sponsor across the most Foralumab trials is Tiziana Life Sciences LTD, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Foralumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: